How Effective is Atomoxetine in Children and Adolescents?

https://www.thecarlatreport.com/podcast/how-effective-is-atomoxetine-in-children-and-adolescents/

 

Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. With the recent approval of another non-stimulant ADHD medication (viloxazine, brand name Qelbree), this is a good time to revisit atomoxetine. How effective is it? What are some of its pros and cons? This podcast will clarify the position of atomoxetine in our toolbox for treating children and adolescents with ADHD. 

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

Addressing Weight Stigma in Clinical Practice

Every patient and family you see is inescapably impacted by weight stigma or fat shaming and the damage from this bias can be lethal. In this podcast, Mara and I help your patients to shield themselves from weight stigma with healthier attitudes.

School Inclusion: What You Need to Know

When a school placement is a bad fit, medication and therapy are unlikely to make much difference. In this episode, we will help you understand and assist your patients to optimize their success in the least restrictive placement.